Author

Amaya López-Pascual

Navarre Institute of Health ResearchORCID 0000-0001-6091-8225Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Molecular Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Organism:human· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2

Frequent Co-Authors

Borja Castelló-UribeiD· 3 shared Carmen BerasainiD· 3 shared Elena Adán-VillaescusaiD· 3 shared Emiliana Valbuena-GoiricelayaiD· 3 shared Iker UriarteiD· 3 shared Jasmin ElurbideiD· 3 shared Maite G. Fernández‐BarrenaiD· 3 shared María ArechederraiD· 3 shared

Activity by Year

2022-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Borja Castelló-UribeORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer BiologyFrontiers in Cell and Developmental BiologyPeer-reviewedJun 4, 2026

Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma

Amaya López-Pascual, Jasmin Elurbide, Emiliana Valbuena-Goiricelaya…·Matias Antonio Avila

This study identifies altered epigenetic regulators and metabolic genes in cholangiocarcinoma, linking them to poor prognosis and metabolic-epigenetic crosstalk.

DOI 10.3389/fcell.2026.1765945

humanmouse

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 29, 2026

Protein arginine-methyltransferase 1 (PRMT1): a new pharmacological target in cholangiocarcinoma

Emiliana Valbuena-Goiricelaya, Jasmin Elurbide, Maria Ujue Latasa…·Matias Antonio Avila

This study identifies PRMT1 as a critical driver of cholangiocarcinoma growth and immune evasion, showing its inhibition enhances antitumor immunity and synergizes with immunotherapy.

DOI 10.64898/2026.05.29.728163

humanbulk RNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologyCell Reports MedicinePeer-reviewedMar 31, 2026

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma

Elena Adán-Villaescusa, Borja Castelló-Uribe, Iker Uriarte…·Maite G Fernandez-Barrena

This study shows that inhibiting G9a enhances the effectiveness of immune checkpoint inhibitors in hepatocellular carcinoma by improving tumor immunogenicity and T cell infiltration.

3 citationstop 2%

mousebulk RNA-seq

𝕏 PostBluesky

Molecular BiologybioRxivPreprintApr 2, 2022

Control of pancreatic islet function and glucose homeostasis by a novel microexon program misregulated in type 2 diabetes

Jonàs Juan‐Mateu, Simon Bajew, Marta Miret-Cuesta…·Manuel Irimia

The paper identifies a microexon program in pancreatic islets regulated by SRRM3, which affects insulin secretion and is linked to type 2 diabetes risk.

DOI 10.1101/2022.04.02.486809

humanmouse

𝕏 PostBluesky